Drug Shortage Report for GD-AMLODIPINE/ATORVASTATIN
| Report ID | 16832 |
| Drug Identification Number | 02362759 |
| Brand name | GD-AMLODIPINE/ATORVASTATIN |
| Common or Proper name | GD-Amlodipine/Atorvastatin |
| Company Name | UPJOHN CANADA ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | AMLODIPINE ATORVASTATIN |
| Strength(s) | 5MG 10MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 90s |
| ATC code | C10BX |
| ATC description | LIPID MODIFYING AGENTS, COMBINATIONS |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | 2017-07-19 |
| Actual start date | |
| Estimated end date | 2017-08-03 |
| Actual end date | 2017-08-03 |
| Shortage status | Resolved |
| Updated date | 2017-08-04 |
| Company comments | Resolved August 3, 2017 |
| Health Canada comments | |
| Contact Address | 17300 TRANS CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-833-287-5646 Email / courriel: UpjohnCanadaCustomerService@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.